Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Hemostemix Inc > My take on these recent developments.......
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by loaddumperon Jan 10, 2025 6:23pm
219 Views
Post# 36398877

My take on these recent developments.......

My take on these recent developments.......Thomas is adding technical expertise through the Cytoimmune agreement that will assist in automating the manufacturing process allowing them to dramatically ramp production. Additionally, the amended agreement tells me the company is no longer issuing 30,000,000 shares at $0.05 for future services as the exchange likely wouldnt approve those terms. This is fantastic for shareholders as the services will be paid in stock at current prices once the services have been delivered. Way less dilutive

Additionally, the volume per clean room per annum with a target of 10 clean rooms @80% takes potential annual sales to ~US$850,000,000 or CDN$1.2 Billion. If they do 10% of that, this is a $10 stock.

I'm cautiously optimistic and look forward to the technology transfer being completed to Cytoimmune and the lab beginning production expected in Q2, 2025. Add a US listing and this should attract some serious eyeballs....
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities